We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
The anti-shigellosis activity of the methanol extract of Picralima nitida on Shigella dysenteriae type I induced diarrhoea in rats
BMC Complementary and Alternative Medicinevolume 13, Article number: 211 (2013)
Picralima nitida Stapf (Apocynaceae) is a medicinal plant used traditionally in Cameroon to cure various ailments such as gastrointestinal disorders and dysentery. This study reports the in vitro and in vivo anti-shigellosis activity of the methanol extract of this plant on rats.
The antimicrobial activity of the extract against pathogenic strains was evaluated using the disc diffusion assay and broth microdilution method. After oral administration of a suspension of Shigella dysenteriae type I (sd1), diarrheic rats were divided into 5 groups; the control group received the vehicle of the extract and the four others 125, 250, 500 mg/kg of the plant extract and ciprofloxacin (20 mg/kg) respectively for 7 days. The frequency of faeces emission as well as the weight of normal and diarrheic faeces was recorded. The presence of stools containing mucus or blood and the number of sd1 in faeces were also recorded.
In vitro, the extract had an antimicrobial effect on 11 out of the 17 pathogenic strains tested. The values of CMI and CMB obtain against Shigella dysenteriae type I were 800 and 6400 μg/ml respectively. In vivo, diarrhoea induction was effective and we notice an increase in faeces frequency and weight (p < 0.05), increase in the percentage of diarrheic stool released as well as the mucus contained in stool (p < 0.05), an increase in bacterial population in stool (p < 0.05). Picralima nitida extract, like ciprofloxacin markedly reduces the frequency faeces released and sd1 density from 100% (diarrheic rats) to 47.22 and 61.69% (500 mg/kg) respectively. It also slowed down the movement of charcoal meal through gastro-intestinal tract with the percentage of intestinal length covered of 60.54 (500 mg/kg).
This anti-shigellosis activity in vitro and in vivo attests the usefulness of Picralima nitida in the traditional treatment of gastrointestinal disorders such as dysentery.
Shigellosis is an infectious disease caused by various species of Shigella: S. boydii, S. dysenteriae, S. flexneri, and S. sonnei. Out of these, S. dysenteriae is found worldwide and concentrated in areas where the population bear the brunt of overcrowding and malnutrition and do not possess adequate waste management and safe drinking water supplies. Shigellosis is associated with 5-15% of cases of diarrhoea and 30-50% of cases of dysentery worldwide. In malnourished children, shigellosis can cause a vicious cycle of further impaired nutrition absorption, recurrent infection, and growth retardation. Without proper care, shigellosis can progress to the life-threatening systemic disease called hemolytic uremic syndrome, which is characterized by thrombocytopenia, hemolytic uremia, and kidney failure. About 3% of persons who are infected with S. flexneri may subsequently develop pains in their joints, irritation of the eyes, and painful urination[5, 6]. This condition called Reiter's syndrome can lead to chronic arthritis which is difficult to treat.
Shigellosis can usually be treated with antibiotics. Antibiotics commonly used are ampicillin, trimethoprim/sulfamethoxazole, nalidixic acid, the fluoroquinolone, ciprofloxacin. Some Shigella have become resistant to antibiotics and inappropriate use of antibiotics to treat shigellosis can make the organisms more resistant in the future. Resistance to quinolone antibiotics has been reported for S. dysenteriae type I (sd1) which rapidly develops resistance to the current therapy[7, 8]. Dominant clone of ciprofloxacin–resistant sd1 was observed in Southeast Asia and in Canada[9, 10]. This situation leads scientists to search for new sources of antimicrobial substances from various sources like medicinal plants[11, 12].
Picralima nitida Stapf (PN) (Apocynaceae) is an entirely glabrous shrub of 3–10 m high, found in African forest region, spanning from Ivory Coast to Zaire and Uganda. Medicinally, the plant is used in the treatment of malaria, male sexual impotence, dysmenorrhoea, gastrointestinal disorders and dysentery. It has been shown to possess anti-trypanosomiac, anti-inflammatory, anti-pyretic and anti-plasmodial properties[14–17]. It has also been shown to possess an activity against Castor oil-induced diarrhea. But the use of this medicinal plant as treatment against gastrointestinal infection as well as against dysentery is based simply on traditional beliefs perpetuated along several generations. The evaluation of the antidysenteric activity in vitro and in vivo of this medicinal plant will offer the best opportunity to understand its rational use in ethno-medicine.
This study reports the antimicrobial properties of methanol (M) extract of PN fruit-rinds against 17 pathogenic species involved in gastrointestinal infection isolated from patients as well as the evaluation of its anti-dysenteric activity as well as activity on gastrointestinal transit in rat model.
The fruit of PN were collected in the morning in Zo-Etélé, Cameroon in September 2011. The identification of the plant was confirmed at the National Herbarium in Yaoundé-Cameroon (reference number of the plant: N° 2136/SRFK). The seeds of the fruits of PN were removed and the fruit-rinds were kept. The plant material (fruit-rinds of PN) was then air dried at room temperature. The dried plant material was ground into a fine powder.
Chemicals and culture media
Mueller Hinton agar and salmonella-shigella agar were purchased from Oxoid, Basingstoke, England; Sabouraud dextrose agar from Merck SA, Sao Paulo, Brazil and Peptone water from HiMedia, Mumbai, India. Antimicrobial susceptibility testing was performed by the disc diffusion method with commercially available disks (Biomerieux F 69260 Charbonnières, France) for Cefoxitin (30 μg), Dibekacine (10 μg) and Clindamycin (10 μg); (Becton, Dickinson and Company Sparks, USA) for Ampicilin (10 μg), Colistin (10 μg), Nitrofurantoine (100 μg), Streptomycin (10 μg), Kanamycin (30 μg), Spectinomycin (25 μg) and Tobramycin (2 μg); (Oxoid, Basingstore, England) for Doxycyclin monohydrate (30 μg), Netilmicin (30 μg), Erythromicin (15 μg), Amoxycillin/Clavulanique (20/10 μg), Amoxicillin (10 μg), Gentamicin (10 μg), Vancomycin (30 μg); (Himedia, Mumbai, India) of ciprofloxacin (5 μg). Gentamicin (Gentamycin injection, 8 mg/2ml, ZMC Hamburg GMBH German), Nystatin (500000 UI, Novadina Pharmaceutical Ltd, London, United Kingdom) and Ciprofloxacin (ZOFLOX, ciprofloxacine 750 mg, Odypharm) used as reference antibiotics for the determination of the MIC and MBC as well as for the in vivo test were purchased from local pharmacy.
This was carried out by soaking the dried powdered plant (250 g) in bottle with 3.5 l of methanol (M) and kept for 72 h. The plant-(M) mixture was then sieved. The filtrate (extract) was concentrated by evaporating under vacuum (M) using a rotating evaporator. The extract was further concentrated by allowing it to stand overnight in an oven at 30°C. The yield of the extraction was calculated by dividing the weight of the extract obtained by the weight of the dried material plant extracted.
Preliminary analysis of chemical constituents such as alkaloids, leucoanthocyanins, flavonoids, saponins, tannins, anthraquinones, polyphenols, coumarins, sterols and/or triterpenes, anthocyanins, cardiac glycosides, reducing sugars, glycosides, anthranoids and steroids was carried out. Those constituents were identified by characteristic colour changes using standard procedures previously described. Each test was qualitatively expressed as negative (−) or positive (+) and the intensity of the characteristic colour was expressed as (++) or (+++).
Test for alkaloids (Meyer reagent)
Fifty milligrams of the tested compound was heated in 10 ml of 2% H2SO4 for 2 min and filtered. To 1 ml of the filtrate, a few drops of the Meyer Reagent was added. The presence of alkaloids was indicated by the obtaining of a white precipitation or turbidity.
Test of flavonoides
Fifty milligrams of the tested compound was introduced in 5 ml of methanol. To it was added some magnesium chip and concentrated hydrochloric acid drop wise. The presence of flavonoids was indicated by the appearance of a violet or brick red coloration with effervescence.
Test for leucoanthocyanines
Fifty milligrams of the tested compound was dissolved in 10 ml distilled water. To 0.5 ml of this mixture was added 2 ml of 2N HCl and heated in a water bath at 100°C. The presence of leucoanthocyanines was indicated by the appearance of red coloration which later changes to violet.
Test for saponins
Fifty milligrams of the tested compound was added to 5 ml of distilled water. After homogenization, the mixture was boiled in 5 min, cooled and filtrated. 5 ml of the filtrate was vigorously agitated for 10 to 30 s. The presence of saponins was indicated by the appearance of foam which persists within 15 min.
Test for tanins
Fifty milligrams of the tested compound was added in 5 ml of distiller water. After mixing, the mixture was boiled for 5 min, cooled and filtrated. 5 ml of 2% NaCl was added to 10 ml of the filtrate and then filtered. The presence of tannins was indicated by the formation of a precipitate after the addition of 1% gelatin to the filtrate.
Test of anthraquinones
Fifty milligrams of the tested compound was diluted in 2 ml of chloroform, homogenized and filtered. Next, 1 ml of 10% NaOH was added to 1 ml of the filtrate. The presence of anthraquinone was indicated by the appearance of a red coloration.
Test of phenols and polyphenols
Fifty milligrams of the tested compound was dissolved in 15 ml distilled water, headed in a water bath for 15 min then cooled and filtered. To 2 ml of the filtrate was added drop wise 1 ml of 1% FeCl3 and 1 ml of 1% K3Fe(CN)6. The presence of polyphenols and phenols was indicated by the apparition of a blue and green precipitate respectively.
Tests of coumarines
On a thin layer chromatographic plate was deposited a spot of the tested compound dissolved in methanol. Next, the plate was exposed to ammoniac vapors. The presence of coumarines was indicated by the appearance of spot whose color varied from blue to purple in the presence of ammoniac.
Test of triterpenes and sterols (Liebermann- burchard test)
Fifty milligrams of the tested compound was dissolved in 2 ml of chloroform and next some drops of acetic anhydride added to the mixture and 1 ml of concentrated H2SO4. The presence of triterpenes was revealed by the apparition of violet-red coloration and sterols by a blue greenish coloration.
Test for anthocyanins
To 50 mg of the tested compound was added 15 ml of a concentrated HCl, the mixture was boiled. The presence of anthocyanins was indicated by the variation of coloration from orange red to orange blue during boiling.
Test for cardiotonic glycosides
In a test tube, 50 mg of the tested compound was dissolved in 2 ml of chloroform. 2 ml of the concentrated H2SO4 was introduced through the walls of the tube. Two phases were formed. The presence of cardiotonic glycosides was indicated by the observation of a brown ring at the interphase.
Test of reducing sugars
Fifty milligrams of the tested compound was dissolved in 10 ml of distilled water, mixed and filtered. In a conical flask containing 4 ml of a Fehling A and B (v/v) liquid mixture, was introduced drop wise of the filtrate. The mixture was boiled; the presence of reducing sugar was indicated by the appearance of a brick red coloration.
Test of glycosides
Fifty milligrams of the tested compound was added to 5 ml of 5% HCl then neutralized with 5 ml 5% NaOH. After homogenization, the mixture was filtered and Fehling liquid test was realized on the filtrate.
Test for anthranoides
Fifty milligrams of the tested compound was added to 2 ml of 0.5 KOH, then 0.5 ml of 5% H2O2 and boiled for 2 min. After cooling, the mixture was filtered. 6 drops of concentrated acetic acid and 3 ml of toluene added to the filtrate. The upper phase (toluene) was transferred to a test tube in which was added 1 ml of 0.5 N KOH. The presence of antranoides was indicated by the appearance of red coloration in the aqueous layer.
Test of steroids
Fifty milligrams of the tested compound was dissolved in 3 ml of chloroform, agitated intermittently for 2 hours and filtered. 1 ml of the filtrate was deposited on a porcelain plate. After evaporation, a drop of sulfuric acid was added, stirred and the color noted. To another portion of the filtrate was added a drop of acetic anhydride and the color noted. The reaction was positive if the same color was obtained for both sulfuric acid and acetic anhydride.
Four weeks old Wistar albino rats (weighing 65–95 g) of both sexes were obtained from the animal house of the Centre for research in Food and Nutrition (CRAN) of the Institute of Medical Research and Medicinal Plant Studies (IMPM), Yaoundé. The rats were given food and water ad libitum. These animals were used for the antimicrobial drug assessment and the study of intestinal transit. Animal housing and the bioassay was conducted in accordance with the internationally accepted principle guidelines of the European Union on Animal Care (CEE Council 86/609). The Cameroon National Ethical Committee approved the protocols of the study (Ref n° FW-IRB 00001954).
The clinical microorganisms included here for the antimicrobial activity screening were the most common strains implicated in gastro-intestinal disorder such as diarrhea and dysentery. There were 15 bacterial and 2 yeast stains : Escherichia coli LMP0101U (E. coli), Klebsiella pneumoniae LMP0210U (K. pneumoniae), Shigella dysenteriae type 1 LMP0504G (S. dysenteriae), Shigella flexneri LMP0313U (S. flexneri), Morganella morganii LMP0904G (M. morganii), Proteus vulgaris LMP0103U (P. vulgaris), Proteus mirabilis LMP0504G (P. mirabilis), Salmonella typhi LMP0209U (S. typhi), Citrobacter freundii LMP0804G (C. freundii), Enterobacter cloacae LMP1104G (E. cloacae), Enterobacter agglomerans LMP1004G (E. agglomerans), Staphylococcus aureus LMP0206U (S. aureus), Streptococcus feacalis LMP0207U (S. feacalis), Pseudomonas aeruginosa LMP0102U (P. aeruginosa), Bacillus cereus T F 3748 (B. cereus T), Candida albicans LMP0204U (C. albicans) and Candida glabrata LMP0205U (C. glabrata). These microorganisms were obtained from Bacteriology and Mycology Laboratories of Centre Pasteur of Yaoundé-Cameroon and Bacillus cereus T was obtained from the Microbiology Laboratory of the Institute of Food Research Reading of Great Britain.
In vitro antimicrobial activity
Disc diffusion assay
The dried plant-extract was dissolved in the same solvent of extraction (M) to a final concentration of 125 mg/ml. Sterile paper disc (6 mm of diameter) prepared from Whatman number one filter paper were impregnated with 10 μl of the crude extract of the plant as described by Edward from a stock of 125 mg/ml. Each disc contains 1.25 mg of the extract. These paper discs were kept in an incubator at 37°C for 24 h to evaporate the solvent. Antimicrobial tests were then carried out by disc diffusion method. 100 μl of the suspension of the tested microorganism (0.5 Mc Farland standard turbidity) containing 108 CFU/ml of bacterial, 106 CFU/ml of yeast prepared from an overnight Mueller Hinton agar culture for bacterial and Sabouraud dextrose agar for yeast was used to seed each prepared and dried Mueller Hinton agar plate for bacteria and Sabouraud dextrose agar for yeast. The discs were arranged and firmly pressed on the agar surface of each seeded plate. These plates, after staying at 4°C for 2 h were incubated aerobically at 37°C for 24 h for bacteria and at 25°C for 24 h for yeast. Similarly, paper discs containing concentration of standard antibiotics (Gentamicin and Nystatin) were prepared and used for the susceptibility test. Negative control was also prepared using the same solvent employed to dissolve the plant extract. Antimicrobial activity was evaluated by measured the zone of inhibition against the tested microorganism and were expressed by – (negative), + (zone of inhibition ≤ 8 mm in diameter), ++ (zone of inhibition > 8 mm and ≤ 20 mm in diameter) and +++ (zone of inhibition > 20 mm in diameter). The result recorded for each bioassay was the average of 3 tests.
Only for S. dysenteriae type 1, a concentration dependent effect of the extract was evaluated using disc diffusion method described above. The reason of this choice was that the strain will later be used to induce bacillary dysentery. The concentrations of the extract tested were 5, 2.5, 1.25 and 0.625 mg. In order to determine their multi-drug resistance profiles, antimicrobial susceptibility testing was performed also against Sd1 by the same method with commercially available disks of Gentamycin 10 μg, Amoxicyclin/clavulanic Acid 20/10 μg, Nitrofurantoin 100 μg, Kanamycin 30 μg, Ampicilin 10 μg, Netilmicin 30 μg, Colistin 10 μg, Erythromycin 15 μg, Ciprofloxacin 5 μg, Amoxycylin 10 μg, Vancomycin 30 μg, Doxycyclin monohydrate 30 μg, Spectinomycin 25 μg, Tobramycin 2 μg, Clindamycin 10 μg, Dibekacin 10 μg, Steptomycin 10 μg and Cefoxitin 30 μg.
Determination of MIC and MBC
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were assessed for the microorganisms that were determined as sensitive to (M) extract of PN in disc diffusion assay using the broth microdilution method. The test was performed in peptone water supplemented with glucose 1% (w/v) with red phenol as a colour indicator (PPG1%). Bacterial strains were cultured overnight at 37°C in Muller Hinton and yeast strains at 25°C in Sabouraud dextrose agar. Test strains were suspended in normal saline (NaCl 9‰), adjusted to 0.5 Mc Farland standard turbidity and suspended in PPG1% to give a final density of 5×105 CFU/ml. For the susceptibility test, the 96-well round bottom sterile plates were prepared by dispensing 180 μl of each inoculated broth into wells. A 20 μl aliquot of the plant extract was added. The concentration of extract used to evaluate the antimicrobial activity was included from 0.39 to 12800 μg/ml. One well was considered as growth control since no extract solution was added. The final volume of each well was 200 μl. The content of each well was mixed and then incubated under normal atmospheric condition at 37°C for 24 h (for bacterial strains) and at 25°C for 24 h (for yeasts strains).
The bacterial and yeasts growth was indicated by the colour change of the well content from the red to yellow. The MIC was defined as the lowest concentration of the extract to inhibit the growth of microorganism. MBC were determined by platting 5 μl sample from red wells on Mueller Hinton agar or on Sabouraud dextrose agar without extract. The MBC was the concentration at which there was not microbial growth. The extract tested in this study was screened three times against each microorganism. Gentamicin for bacteria strains and Nystatin for yeast strains at the concentration range of 0.019 to 320 μg/ml was prepared in (PPG1%) and used as standard drugs for the positive control. The susceptibility of the sd1 to antibiotic Ciprofloxacin which shown the great activity against sd1 in disc diffusion assay was also performed by liquid dilution method and served as positive control.
In vivo antimicrobial activity
Thirty rats were individually kept in metabolic cage during a period of observation of 7 days before diarrheal induction. Diarrhoea was induced in rats using sd1 strains. The turbidity of the sd1 inoculum was matched spectrophotometrically at 450 nm to 4 McFarland standards. After verifying that the rats were not sd1 carriers, they were orally administrated with 1 ml of the saline diluted inoculum. Diarrheic rats were randomly divided into 5 groups, each containing six animals. When diarrhoea appeared, animal were administrated the anti-diarrheic drugs daily by the oral route for 7 consecutive days: The first group (diarrheic control) received the vehicle of the extract (0.5% Tween 80 in distilled water); the second group received the antibiotic ciprofloxacin (20 mg/kg of body weight (bw) and the remaining three groups were given orally 125, 250, and 500 mg/kg bw of M extract of PN.
Animals were observed daily for behavioural changes and mortality patterns once before induction, during induction and up to 7 days after induction. The stools of each animal were also collected daily using a white cloth fixed under the bars supporting the animal in the metabolic cage during all the experiment period. Then, the frequency and weight of normal and diarrheic faeces were recorded. The presence of stools containing mucus or blood was also noted daily at each experimental period. Enumeration of sd1 in faeces was performed before diarrheal induction to make sure that the rats are not sd1 carriers, after the appearance of diarrhoea and once every day during the 7 days of treatment. For this purpose, 0.5 mg of faeces was homogenized in 4.5 ml of sterile saline; serial of dilution were made and 50 μl of each dilution was seeded over salmonella-shigella agar. After 24 h of incubation at 37°C, the number of CFU was determined.
Study of small intestinal transit
This was done according to the method proposed by Mujumdar using charcoal meal as a diet marker. The rats were divided into 4 groups of 6 animals each. The first group (the control group) was orally administered the vehicle. The second and third groups orally received M extract of PN, 250 mg/kg and 500 mg/kg bw respectively. The fourth group also orally received the standard drug, atropine sulphate (5 mg/kg bw). 30 min after administration, each animal was given 1 ml of charcoal meal orally (10% activated charcoal in 5% gum acacia). Also, 30 min after this administration, each animal was sacrificed and the distance covered by the charcoal meal in the intestine, from the pylorus to the caecum was measured and expressed as a percentage of distance moved.
The results are expressed as means ± standard deviation. Bacterial densities were expressed in log10 before analysis. Data were statistically evaluated using the analysis of variance following by the paired t-student’s test. The differences between groups were considered significant at p < 0.05.
The yield of the extraction was 5% w/w. Phytochemically analysis revealed the presence of alkaloids, flavonoids, saponins, polyphenols, cardiac glycosides and glycosides in which alkaloids, and polyphenols were major compounds (Table 1).
In vitro antimicrobial activity
The antimicrobial activity of the fruit-rinds of PN extracts against microorganisms examined in the present study and their potency were qualitatively and quantitatively assessed by the presence or absence of inhibition zone and zone diameter, MIC and MBC values. The results are given in the Tables 2 and3.
The (M) extract of PN had antibacterial effect on 11 out of 17 rats involved in either diarrhea, dysentery or other gastrointestinal disorders (Table 2). The antimicrobial effect of this extract was found to be comparable to that of the conventional antibacterial (Gentamycin) and antifungal (Nystatin) drug used in this study. Maximal inhibition zone values for the microorganisms sensitive to the (M) extract of PN was 21.83 mm against the Gram-negative bacterium P. vulgaris (Table 2).
Considering that in this study crude extract was employed, the MIC values of 8 mg/ml or below against any microorganism tested was considered as active. The best MIC and MBC values for the microorganisms tested were 0.78 and 1.525 μg/ml respectively (Table 3). The greater and remarkable antimicrobial activity of the extract was recorded with P. vulgaris. Antimicrobial activity of the extract of PN was least observed with C. albicans and E. cloacae, the two fungal strains used.
A concentration dependent effect of the extract against sd1 was observed with agar diffusion method. The inhibition diameter began at 0.625 mg (Ø= 8.33 mm) and increase progressively up to 24.5 mm for 5 mg. The result of the antimicrobial susceptibility test performed with commercially available discs has revealed that sd1 strain included here was resistant to Kanamycin, Tobramycin, Clindamycin, Amoxicyclin/Clavulanic acid, Amoxycylin, Cefoxitin and Ampicilin (Table 4). The highest strain sensitivity was obtained with Ciprofloxacin and was confirmed by data from literature. The values of CMI and CMB obtained were 800 and 6400 and 0.07 and 0.312 μg/ml for PN and Ciprofloxacin respectively.
In vivo antimicrobial activity
Animal behaviour, stool quality and mortality
The animals showed behavioural changes 3 hours after the administration of the inoculum. The changes which lasted 2 to 3 days of treatment, included lethargy, disorientation, seizures. The first diarrheic stool was emitted within 24 hours after the induction. Diarrheic stools were either soft or liquid, containing mucus and smooth and very often mucus-linked. During the 7 days of treatment, no death was observed, except in the groups of animal receiving the vehicle and the dose of 125 mg of the extract where 83.33 and 50% of deaths were respectively registered at the end of the experimental period (Table 5).
Stool bacterial density
In the stools of diarrheic control rats, sd1 density increased significantly from the first day after induction to the last day of the treatment compared with the initial value administered. Compared with the diarrheic control and the initial value administered, the antibiotic ciprofloxacin significantly reduced the density of sd1 in the stool from the first to the last day of the treatment. Similar to ciprofloxacin, PN inhibited the bacterial growth in a dose depended manner. PN extract at the dose 125 mg/kg inhibited bacterial growth by the 3rd day but maintaining the sd1 density at a level slightly inferior to the value administered. The extract at the dose of 250 and 500 mg/kg effectively reduced sd1 density from the 3rd day of therapy and beyond; the percentage of reduction of sd1 density was respectively 61.69 and 65.67% compared to the value administrated (Figure 1).
Frequency and mass of normal and abnormal stool
The study shows that standard drug and the extract markedly reduced the frequency of faeces released from 100% (diarrheic rats) to 47.22 and 79.16 (125 mg/kg) to 48.61% (250 and 500 mg/kg) respectively. From the 2nd day of the treatment, the total faeces frequency, while increasing in control diarrheic rats, decreased in all the treated rats. This reduction was significant from the 3rd day in rats receiving standard drug, 250 and 500 mg/kg of the extract. The average weight of defecate in the control group at the end of the treatment was 3.58 g. Treatment with each dose of the medicinal plant extract significantly reduced the weight of the defecation to 41.35 (125 mg/kg) - 49.35% (500 mg/kg) compared with control group (Figures 2 and3).
The rats that did not receive the medicinal plant extract or standard drug showed typical symptoms of shigellosis along with watery, frequent defecation and frequent mucous stools. The percentage of diarrheic and mucus contained in stools of the survival animal in the control group were respectively 95.238 and 61.90% at the end of the treatment. Treatment with each dose of the medicinal plant extract significantly reduced the percentage of diarrheic stools to 38.88 (125 mg/kg) – 0.00% (500 mg/kg) compared with control group. Like diarrheic stool, mucus contained in stool also reduced with the treatment. The percentage of mucus contained in stool were 1.00 (125 mg/kg) to 0.00% (250 and 500 mg/kg) at the end of the treatment (Tables 6 and7).
Effect of PN-M on charcoal-induced gut in transit changes
The administration of PN-M also slowed down the movement of charcoal meal through gastro-intestinal tract compared to the castor oil-treated rats. The percentage of intestinal length covered by charcoal meal in PN-M pre-treated (250 and 500 mg/kg) and castor oil-treated rats was 58.27, 60.54 and 74.57 respectively. Atropine on its part, produced a marked decrease in the propulsive movement and the intestinal length covered by charcoal meal was 40.33 (Table 8).
The (M) extract of PN fruit-rinds showed a promising broad spectrum antibacterial property, inhibiting 80% of bacterial strains tested, especially P. vulgaris, E. coli and S. aureus with MBC ranging between 0.78 and 1.56 μg/ml. The presence of flavonoids, saponins, tannins and alkaloids in this extract as shown in Table 1 may explain some of its antimicrobial action since antimicrobial action of most of these phytochemical substances has been demonstrated[25–28]. These results are interesting since these microorganisms are commonly involved in acute diarrhoea diseases. Our data confirm previous results about antimicrobial activity of this plant. It has been shown that other parts (seed, root and stem bark) of Picralima nitida has significant antimicrobial activity[29, 30]. To the best of our knowledge, this is the first time that the antimicrobial activity of the fruit-rind of this plant is reported.
The extract shows a concentration dependent effect against sd1. This inhibiting activity of the extract against sd1 was also confirmed by the sd1 count in stools, where the decrease of bacterial population was observed by the 3rd and 5th day of treatment with both extract and standard antibiotic used. Ciprofloxacin is a bactericidal synthetic antibiotic belonging to fluoroquinolone family. It has been recognized to have a great activity against sd1. Our data confirms this assertion since the great sensitivity of sd1 was observed with ciprofloxacin on the 18 standard antibiotics used. It acts by inhibiting the activity of DNA gyrase and thereby preventing the supercoiling of the bacterial chromosome. Consequently, the bacterial can no longer pack its DNA into the cell.
S. dysenteriae causes dysentery by invading the colonic mucosa. Following host epithelial cell invasion and penetration of the colonic mucosa, Shigella infection is characterized by degeneration of the epithelium and inflammation of the lamina propria. This results in desquamation and ulceration of the mucosa, and subsequent leakage of blood, inflammatory elements and mucus into the intestinal lumen. Patients suffering from Shigella infection will therefore pass frequent, scanty, dysenteric stool mixed with blood and mucus, since, under these conditions, the absorption of water by the colon is inhibited. Many diarrheic rats showed typical symptoms of shigellosis, along with watery, frequent defecation and frequent mucoid stools. Abnormalities of the central nervous system including lethargy, disorientation, seizures and paralysis were also observed within those animals. The multiplication of sd1 within colonic epithelial cells, causing cell death, and spreading laterally to infect and kill adjacent epithelial cells was suspected to being responsible for those typical signs that occurred within 2 days after induction. In addition, the signs of neurotoxicity and deaths observed within diarrheic animals may be due to shiga-toxin since it has been documented. Symptoms of shigellosis in rats reduced significantly with both Ciprofloxacin and extract treatment with respect to the reduction of sd1 density in stool. This result confirms the antimicrobial activity of the extract in vitro and vivo.
PN-M significantly reduced intestinal transit as observed by the decrease in intestinal motility of charcoal meal. Probably extract increased the reabsorption of water thereby decreasing intestinal motility as observed by the decrease in intestinal transit of charcoal meal. The delay in faecal emptying by the extract allows more time for fluid absorption and subsequently reduces fluid loss in the stool. Decrease in intestinal transit induce by the extract could have lead to an increase of enteroinvasive infections, but this might have been prevented by the antimicrobial properties of the extract. Earlier studies have shown that anti-dysenteric and anti-diarrhoeal properties of medicinal plants were found to be due to tannins, alkaloids, saponins, flavonoids, sterol and/or triterpenes and reducing sugars[33, 34]. Thus, alkaloids, saponins and flavonoids content of this plant extract may be responsible for its anti-diarrhoeal property.
S. dysenteria type 1 strain was resistant to all antibiotics from the beta-lactam family used in this study. The great sensibility of the strain was obtained with ciprofloxacin, a synthetic antibiotic belonging to fluoroquinolone family. The (M) extract of PN had antimicrobial activity on 11 out of 17 microorganisms tested amongst witch S. dysenteriae type 1. The values of CMI and CMB obtain against this strain were 800 and 6400 μg/ml respectively. This anti-Shigella activity of PN was also shown in vivo. The administration of PN extract to diarrheic rats significantly reduced the bacterial population in stools; thereby reduce the symptoms of shigellosis on rats.
At present, our group is concerned with the fractionation and the isolation of pure compounds of the crude extracts and the elucidation of their structures in order to better evaluate their pharmacological activity in vitro and in vivo.
Niyogi S: Shigellosis. J Microbiol. 2005, 43: 133-143.
Meicler C, Cerf M: Diarrhées a shigelles, a colibacilles entero-invasifs, entero-hémorragiques et a colibacilles. diarrhées aigues infectieuses. 1993, Dion Paris, 9-98.
Keusch GT: Shigella infections. Clin Gastroenterol. 1979, 8: 645-662.
Griffin PM, Tauxe RV: The epidemiology of infections caused by Echerichia coli 0157: H7 and the associated hemolytic uremic syndrome. Epidemiol Rev. 1991, 13: 60-98.
Struelens MJ, Patte D, Kabir I, Salam A, Nath SK, Butler T: Shigella septicemia: prevalence, presentation, risk factors and outcome. J Infect Dis. 1985, 152: 784-790. 10.1093/infdis/152.4.784.
Lipsky PE, Fosmire S, Stieglitz H: Bacterial epitopes involved in induction of reactive arthritis. Am J Med. 1988, 85: 56-58.
Dutta S, Ghosh A, Ghosh K, Dutta D, Bhattacharya SK, Nair GB: Newly emerged multiple antibiotic-resistant Shigella dysenteriae type 1 strains in and around Kolkatta, India, are clonal. J Clin Microbiol. 2003, 41: 5833-5834. 10.1128/JCM.41.12.5833-5834.2003.
Sivapalasingam S, Nelson JM, Joyce K, Hoekstra M, Angula FJ, Mintz ED: High Prevalence of Antimicrobial Resistance among Shigella Isolates in the Unated States Tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob Agents Chemother. 2006, 50: 49-54. 10.1128/AAC.50.1.49-54.2006.
Dutta S, Dutta D, Dutta P, Matsushita S, Bhattacharya SK, Yoshida SI: Shigella dysenteriae type1, Kolkatta, India. Emerg Infect Dis. 2003, 9: 1471-1474. 10.3201/eid0911.020652.
Pazhani GP, Sarkar B, Ramamurthy T, Bhattacharya SK, Takeda Y, Niyogi SK: Clonal multidrug-resistant Shigella dysenteriae type 1 strains associated with epidemic and sporadic dysenteries in eastern Indian. Antimicrob Agents Chemother. 2004, 48: 681-684. 10.1128/AAC.48.2.681-684.2004.
Clark AM: Natural products as resource for new drugs. Pharmaceutical research. 1996, 13: 1133-1141. 10.1023/A:1016091631721.
Cordell GA: Biodiversity and drug discovery a symbiotic relationship. Phytochemistry. 2000, 55: 463-480. 10.1016/S0031-9422(00)00230-2.
Adjanohoun JE, Aboubakar N, Dramane K, Ebot ME, Ekpere JA, Enow-Orock EG, Focho D, Gbile ZO, Kamanyi A, Kamsu Kom J, Kieta A, Mbenkum T, Mbi CN, Mbiele L, Mbome IL, Mubiru NK, Nancy WL, Nkongmeneck B, Satabie B, Sofowora A, Tamze V, Wirmum CK: Contribution to Ethnobotanical and Floristic Studies in Cameroon: Traditional Medicine and Pharmacopoeia. 1996, Lagos: Technical and Research Commission of Organisaion of African Unity (OAU/STRC), 60-61.
Wosu LO, Ibe CC: Use of extract of Picralima nitida bark in the treatment of experimental trypanosomiasis: a preliminary study. J Ethnopharmacol. 1989, 25: 263-268. 10.1016/0378-8741(89)90032-9.
Ezeamuzie K, Ojinnaka MC, Uzogara EO, Oji SE: Anti-inflammatory, antipyretic and antimalarial activities of a West African medicinal plant: Picralima nitida. Afr J Med Med Sci. 1994, 23: 85-90.
Iwu MM, Klayman Daniel L, Jackson Joan E, Tally John D, Andersen Steven L: Alkaloids of Picralima nitida used for treatment of protozoal diseases. United States Patent. 1994, 5: 553-
François G, Aké Assi L, Holenz J, Bringmann G: Constituents of Picralima nitida display pronounced inhibitory activities against asexual erythrocytic forms of plasmodium. J. ethnopharmacol. 1996, 54: 165-168. 10.1016/S0378-8741(96)01458-4.
Kouitcheu Mabeku LB, Penlap Beng V, Kouam J, Ngadjui BT, Fomum ZT, Etoa FX: Evaluation of Antidiarrhoeal Activity of the fruit-rind of Picralima nitida (Apocynaceae). Afr J Trad CAM. 2006, 3: 66-73.
Harbone JB: Phytochimical methods: a guide to modern techniques of plants analysis. 1988, London: Chapman and Hall, 1-867.
Edward DI: Antimicrobial Action. 1980, London and Basingstoke: The Macmillan Press, 8-30. 1
Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH: Manual of Clinical Microbiology. 1995, Washington, DC: ASM Press, 1327-1341. 6
NCCLS: Methods for determining bactericidal activity of antimicrobial agents. 1999, Wayne Pa, Approved guideline, M26-A, National Committee for Clinical Laboratory Standards
Mujumdar AM: Antidiarrhoeal activity of Azadiachta indica leaf extract. Indian Drugs. 1998, 35: 417-420.
OMS: Directives pour la lutte contre les shigelloses y compris lors des épidémies dues a shigella dysenteriae type I. 2005, Genève Switzerland: bull de l’OMS, 69-
Lewis WH, Elvin-Lewis MPF: Plants Affecting Man’s Health. Medicinal Botany. 1977, London: Wiley, 515-
Plasuntherum C, Iyer K: Antimicrobial activity of Coscinium fenetratum Colebr. against clostridium tetani. Indian J Med Res. 1982, 76: 71-76.
Palacious P, Gutkind G, Randina RVD, De Torres R, Coussio JD: Antimicrobial activity of B. crispa and B. notosergila. Genus Baccharis II. Planta Med. 1983, 49: 128-10.1055/s-2007-969832.
Ahmad A, Khan HA, Ahmad YU, Qazi S: Antibacterial activity of juliflorine isolated from Prosopis juliflora. Planta Med. 1986, 4: 285-288.
Fakeye TO, Itiola OA, Odelola HA: Evaluation of the antimicrobial property of the stem barks of Picralima nitida (Apocynaceae). Phytother Res. 2000, 14: 368-370. 10.1002/1099-1573(200008)14:5<368::AID-PTR615>3.0.CO;2-X.
Nkere CK, Iroegbu CU: Antibacterial screening of the root, seed and stem bark extracts of Picralima nitida. Afr J Biotechnol. 2005, 4: 522-526.
Alcamo Edward I: Fundamentals of Microbiology: Chemotherapeutic Agents and Antibiotics. 1983, Addison-Wesley Publishing Company, Inc, 669-691.
Cherla R, Lee S, Vernon T: Shiga toxins and apoptosis. FEMS Microbiol Lett. 2003, 228: 159-166. 10.1016/S0378-1097(03)00761-4.
Galvez J, Zarzuelo A, Crespo ME: Antidiarrhoeic activity of Scleroarya birrea bark extract and its active tannin constituent in rats. Phytother Res. 1991, 5: 276-278. 10.1002/ptr.2650050611.
Vercruysse A, Foriers A, Longanga Otshudi A: Contribution to the ethnobotanical, phytochemical and pharmacological studies of traditionally used medicinal plants in the treatment of dysentery and diarrhoea in Lomela area, Democratic Republic of Congo (DRC). J Ethnopharmacol. 2000, 71: 411-423. 10.1016/S0378-8741(00)00167-7.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/211/prepub
We are grateful to the Bacteriology and Mycology Laboratories of Centre Pasteur Yaoundé and the Microbiology Laboratory of the Institute of Food Research Reading of Great Britain for giving us microorganisms. We are also grateful to Mr. Nelson SONELA for reading through the manuscripts and making some language corrections.
The authors declare that they have no competing interests.
JK conducted experiments on phytochemical screening and LBKM on antimicrobial and anti-shigellosis activity of tested plant extract. JLT participated in design of the study and preparation of the manuscript. All the authors read and approved the final manuscript.